579P Methodological considerations for clinical equivalence of bevacizumab biosimilars

Autor:	B. Heinzmann
Rok vydání:	2016
Předmět:	medicine.medical_specialty Oncology Bevacizumab business.industry Medicine Medical physics Biosimilar Hematology business Equivalence (measure theory) medicine.drug
Zdroj:	Annals of Oncology. 27:ix188
ISSN:	0923-7534
Databáze:	OpenAIRE
Externí odkaz:	https://explore.openaire.eu/search/publication?articleId=doi_________::edb122901ba979bba21c2cd2af538221 https://doi.org/10.1016/s0923-7534(21)00737-7 Zobrazit plný text záznamu